BioCentury | Mar 24, 2003
Company News

Pharmagenesis, Pierre Fabre deal

...received rights to develop, manufacture and market PG490-88Na worldwide, excluding Taiwan, China and Hong Kong. Pharmagenesis...
...the compound. Pharmagenesis will receive an upfront fee and is eligible for milestones and royalties. Pharmagenesis...
...PhytoHealth joint venture and in China and Hong Kong through its Tianjin Hualong joint venture. Pharmagenesis Inc....
BioCentury | Nov 11, 2002
Clinical News

PG490-88Na: Phase I

...of intravenous PG490-88Na in 30 patients with advanced solid tumors who have failed standard therapy. Pharmagenesis Inc....
BioCentury | Sep 30, 2002
Company News

Pharmagenesis, Fujisawa deal

...The companies will research the use of triptolide derivatives from Pharmagenesis to treat autoimmune conditions. Fujisawa...
...conditions. Fujisawa has an option to acquire the exclusive worldwide development and marketing rights to Pharmagenesis'...
...the principle active component of the traditional Chinese medical plant called Tripterygium wilfordii Hook F. Pharmagenesis Inc....
BioCentury | Nov 23, 1998
Clinical News

Advanced Magnetics, Pharmagenesis regulatory update

...Pharmagenesis has exclusive distribution rights in China and Taiwan. Advanced Magnetics Inc. (AVM), Cambridge, Mass. Pharmagenesis Inc....
BioCentury | Sep 8, 1998
Company News

Calydon management update

...Cancer Hired: Robert Tidwell as VP of business development, formerly VP and general manager at Pharmagenesis Inc. WIR...
BioCentury | Dec 23, 1996
Company News

Pharmagenesis, President Pharmaceutical Corp., Suzhou Bureau of Public Health deal

...SPP Ltd. (Suzhou, China), a joint venture to manufacture and commercialize Pharmagenesis' products in China. Pharmagenesis...
...and regulatory submissions. President Pharmaceutical is the largest shareholder, while Pharmagenesis is the second largest. Pharmagenesis...
...Chinese Phase I trials of PG2, which is derived from traditional Chinese medicine (see B13). Pharmagenesis Inc....
BioCentury | Dec 23, 1996
Clinical News

PG2 based on Chinese medicine: Phase I testing

Pharmagenesis Inc. , Palo Alto, Calif. Product: PG2 based on Chinese medicine Indication: Alleviate neutropenia, thrombocytopenia, and anemia from chemotherapy in cancer Status: Began Phase I testing in China. (Joint venture formed, B7.) WIR Staff...
BioCentury | Dec 9, 1996
Company News

Advanced Magnetics, Pharmagenesis sales and marketing update

...in the U.S., Japan, South Korea, Europe and Brazil. Advanced Magnetics Inc. (AVM) Cambridge, Mass. Pharmagenesis Inc....
BioCentury | Nov 11, 1996
Company News

Pharmagenesis, Eli Lilly deal

...antifungal agents derived from microorganisms associated with plants known to be resistant to fungal infections. Pharmagenesis's...
...that demonstrate antifungal activity. Lilly is responsible for preclinical and clinical development of lead compounds. Pharmagenesis...
...product rights to applications for cardiovascular diseases, CNS diseases, cancer, infectious diseases, and hormonal disorders. Pharmagenesis Inc....
BioCentury | May 15, 1995
Company News

Alza deal

...Corp. (AZA) Pharmagenesis Inc. (Palo Alto) will commercialize Testoderm in China, Hong Kong, Macau and Taiwan. Pharmagenesis...
...OROS pseudoephedrine, in those four countries as well as Indonesia, Malaysia, Sing-apore, Thailand and Vietnam. Pharmagenesis...
Items per page:
1 - 10 of 11
BioCentury | Mar 24, 2003
Company News

Pharmagenesis, Pierre Fabre deal

...received rights to develop, manufacture and market PG490-88Na worldwide, excluding Taiwan, China and Hong Kong. Pharmagenesis...
...the compound. Pharmagenesis will receive an upfront fee and is eligible for milestones and royalties. Pharmagenesis...
...PhytoHealth joint venture and in China and Hong Kong through its Tianjin Hualong joint venture. Pharmagenesis Inc....
BioCentury | Nov 11, 2002
Clinical News

PG490-88Na: Phase I

...of intravenous PG490-88Na in 30 patients with advanced solid tumors who have failed standard therapy. Pharmagenesis Inc....
BioCentury | Sep 30, 2002
Company News

Pharmagenesis, Fujisawa deal

...The companies will research the use of triptolide derivatives from Pharmagenesis to treat autoimmune conditions. Fujisawa...
...conditions. Fujisawa has an option to acquire the exclusive worldwide development and marketing rights to Pharmagenesis'...
...the principle active component of the traditional Chinese medical plant called Tripterygium wilfordii Hook F. Pharmagenesis Inc....
BioCentury | Nov 23, 1998
Clinical News

Advanced Magnetics, Pharmagenesis regulatory update

...Pharmagenesis has exclusive distribution rights in China and Taiwan. Advanced Magnetics Inc. (AVM), Cambridge, Mass. Pharmagenesis Inc....
BioCentury | Sep 8, 1998
Company News

Calydon management update

...Cancer Hired: Robert Tidwell as VP of business development, formerly VP and general manager at Pharmagenesis Inc. WIR...
BioCentury | Dec 23, 1996
Company News

Pharmagenesis, President Pharmaceutical Corp., Suzhou Bureau of Public Health deal

...SPP Ltd. (Suzhou, China), a joint venture to manufacture and commercialize Pharmagenesis' products in China. Pharmagenesis...
...and regulatory submissions. President Pharmaceutical is the largest shareholder, while Pharmagenesis is the second largest. Pharmagenesis...
...Chinese Phase I trials of PG2, which is derived from traditional Chinese medicine (see B13). Pharmagenesis Inc....
BioCentury | Dec 23, 1996
Clinical News

PG2 based on Chinese medicine: Phase I testing

Pharmagenesis Inc. , Palo Alto, Calif. Product: PG2 based on Chinese medicine Indication: Alleviate neutropenia, thrombocytopenia, and anemia from chemotherapy in cancer Status: Began Phase I testing in China. (Joint venture formed, B7.) WIR Staff...
BioCentury | Dec 9, 1996
Company News

Advanced Magnetics, Pharmagenesis sales and marketing update

...in the U.S., Japan, South Korea, Europe and Brazil. Advanced Magnetics Inc. (AVM) Cambridge, Mass. Pharmagenesis Inc....
BioCentury | Nov 11, 1996
Company News

Pharmagenesis, Eli Lilly deal

...antifungal agents derived from microorganisms associated with plants known to be resistant to fungal infections. Pharmagenesis's...
...that demonstrate antifungal activity. Lilly is responsible for preclinical and clinical development of lead compounds. Pharmagenesis...
...product rights to applications for cardiovascular diseases, CNS diseases, cancer, infectious diseases, and hormonal disorders. Pharmagenesis Inc....
BioCentury | May 15, 1995
Company News

Alza deal

...Corp. (AZA) Pharmagenesis Inc. (Palo Alto) will commercialize Testoderm in China, Hong Kong, Macau and Taiwan. Pharmagenesis...
...OROS pseudoephedrine, in those four countries as well as Indonesia, Malaysia, Sing-apore, Thailand and Vietnam. Pharmagenesis...
Items per page:
1 - 10 of 11